

Market Announcement



29 October 2026

Noxopharm Limited (ASX: NOX) – Suspension from Quotation

The securities of Noxopharm Limited ('NOX') will be suspended from quotation immediately under Listing Rule 17.2 at the request of NOX, pending the release of an announcement by NOX.

Unless ASX decides otherwise, the securities will remain suspended until the earlier of:

- the end of the period stated in NOX's request for voluntary suspension; or
- the release of the announcement to the market.

NOX's request for voluntary suspension is attached below for the information of the market.

Issued by

ASX Supervision



29 October 2026

ASX Limited
Listings Compliance, Melbourne
Level 45, South Tower
525 Collins Street
Melbourne VIC 3000

By email only: tradinghaltsmelbourne@asx.com.au

Dear Manager,

Noxopharm Limited (ASX: NOX): Request for Voluntary Suspension

Further to the Company's request of 26 October 2026 for the Company's securities to be placed in trading halt, the Company hereby requests that its securities be placed in voluntary suspension from the commencement of trading on Thursday, 29 October 2026 in accordance with ASX Listing Rule 17.2, pending release of an announcement in relation to a capital raising.

The Company requests that the voluntary suspension remain in place until the earlier of the commencement of trading on Monday, 2 November 2026 or the release of the announcement referred to above.

The Company is not aware of any reason why the voluntary suspension should not be granted, or of any other information necessary to inform the market about the suspension.

Please contact Shawn van Boheemen, Company Secretary, on 0414 903 376 or at shawn.vanboheemen@noxopharm.com if ASX requires any further information.

Yours faithfully,

A handwritten signature in black ink, appearing to read 'S van Boheemen', with a long horizontal flourish extending to the right.

Shawn van Boheemen Company Secretary
Noxopharm Limited